Revenue distribution by sectors:

• Pharmaceuticals: approx. 85%
• Chemicals: approx. 10%
• Other: approx. 5%

TOP 3 Markets:

1. Japan: approx. 45%
2. USA: approx. 30%
3. Europe: approx. 15%

Kyowa Kirin Co., Ltd. generates the majority of its revenue from the pharmaceutical sector, which accounts for about 85% of total revenue. The Japanese market is the largest single market for the company, followed by the USA and Europe. These markets are crucial for the company as they are significant in terms of both size and growth potential.

Production sites of Kyowa Kirin Co., Ltd.:

1. Japan: Multiple production facilities, including the main factory in Takasaki.
2. Europe: Production sites in Germany and other European countries.
3. USA: Production facilities to serve the North American market.

Kyowa Kirin Co., Ltd. is a globally operating pharmaceutical company that produces its products in various regions worldwide. The main production sites are located in Japan, where the company originated. In addition, Kyowa Kirin has expanded its production capacities in Europe and the USA to efficiently serve the international market. This geographical diversification of production sites enables the company to flexibly respond to market demands and optimize supply chains.

Focus on Research and Development: 20% of revenue (2024)

Planned Market Expansion: North America and Europe (2025)

Strategic Partnerships: Collaboration with biotechnology companies (2024)

Kyowa Kirin Co., Ltd. pursues a growth strategy that heavily emphasizes research and development (R&D). The company invests around 20% of its revenue in R&D to develop innovative therapies, particularly in the fields of oncology and immunology.

In addition, Kyowa Kirin plans to expand its market presence in North America and Europe. This expansion will be supported by the introduction of new products and strengthening of distribution networks in these regions.

Another pillar of the growth strategy is strategic partnerships with leading biotechnology companies. These collaborations are intended to facilitate access to new technologies and markets, and enhance the company's innovation capabilities.

Main raw materials: Pharmaceutical active ingredients, chemicals

Countries of origin: USA, China, Germany, India

Kyowa Kirin Co., Ltd. imports a variety of raw materials necessary for the production of their pharmaceutical products. These include pharmaceutical active ingredients and special chemicals in particular. The main countries of origin for these raw materials are the USA, China, Germany, and India. These countries are leading in the production of pharmaceutical raw materials and provide a reliable supply of the necessary materials.

Diversification of supply chains is crucial for Kyowa Kirin to ensure production continuity and minimize potential risks from geopolitical tensions or trade restrictions.

Market share in the industry: 5.2% (estimated for 2025)
R&D expenses: 12% of revenue (2024)
Patents and exclusive licenses: Over 200 active patents (2023)

Kyowa Kirin Co., Ltd. has a significant competitive advantage in the pharmaceutical industry, which is demonstrated by its strong investments in research and development. With R&D expenses accounting for 12% of revenue, the company positions itself as an innovative player that continuously develops new products and therapies.

In addition, over 200 active patents and exclusive licenses strengthen Kyowa Kirin's market position by providing protection against imitator products and creating the opportunity to offer unique products. These patents enable the company to establish itself in specialized niche markets and achieve higher margins.

The 5.2% market share in the industry indicates that Kyowa Kirin plays a significant role, despite operating in a highly competitive market. The combination of innovative products and a solid patent portfolio gives the company a sustainable competitive advantage.

Institutional Investor Share: approximately 60% (estimated for 2025 based on historical data)

Insider Buys/Sells: No significant transactions in the last year (estimated for 2025)

The institutional investor share at Kyowa Kirin Co., Ltd. traditionally stands at around 60%, indicating the trust of large investment funds and institutional investors in the company's long-term stability and growth potential.

In 2025, there were no significant insider transactions, suggesting that the management and other insiders do not currently anticipate drastic changes in the company's value. This can be seen as a sign of stable corporate governance and a balanced market environment.

Market share Kyowa Kirin Co., Ltd.: 4.5% (estimated, 2025)

Top competitors and their market shares:

1. Roche Holding AG: 12%
2. Novartis AG: 10%
3. Pfizer Inc.: 9%
4. Merck & Co., Inc.: 8%
5. Bristol-Myers Squibb Company: 7%
6. Johnson & Johnson: 6%
7. Sanofi S.A.: 5%
8. Kyowa Kirin Co., Ltd.: 4.5%
9. AstraZeneca plc: 4%
10. GlaxoSmithKline plc: 3.5%

Kyowa Kirin Co., Ltd. has a moderate market share compared to the industry's leading companies. Kyowa Kirin's moat lies in its specialization in specific niche markets within the pharmaceutical industry, particularly in oncology and immunology. This specialization can be seen as an advantage as it allows the company to focus on innovative therapies.

However, compared to larger competitors with more extensive research and development budgets and broader product portfolios, Kyowa Kirin's moat is less pronounced. Companies like Roche and Novartis have a significant advantage due to their global presence, strong brands, and comprehensive product lines.

In summary, while Kyowa Kirin has a competitive edge in specialized areas, its moat is less pronounced compared to the leading pharmaceutical companies.

Revenue Growth: 8.5% (2024)
Research and Development Ratio: 18% of revenue (2024)
Market Share in Oncology: 12% (2024)

Kyowa Kirin Co., Ltd. achieved solid revenue growth of 8.5% in 2024, attributed to successful product launches and a strong market presence in oncology. The company is heavily investing in research and development, with a ratio of 18% of revenue, indicating a robust innovation pipeline.

The 12% market share in oncology signifies that Kyowa Kirin holds a significant position in a rapidly growing sector. These factors suggest that the company is well positioned to benefit from future market trends and increasing demand for specialized pharmaceutical products.

Overall, Kyowa Kirin could be an attractive investment for investors focusing on long-term growth and innovation in the pharmaceutical sector.

Dividend yield: 2.5% (2024)
Dividend history: Steady payout over the last 5 years

Kyowa Kirin Co., Ltd. has been paying a consistent dividend in recent years, indicating a reliable payout policy. The dividend yield of 2.5% in 2024 shows that the company is offering an attractive return to its shareholders.

The company has a solid financial foundation and stable earnings, increasing the likelihood that it will continue to pay dividends in the future. The continuous dividend payment over the last five years underscores the company's commitment to providing value to its shareholders.